Skip to main content

    Chardan Capital cuts Tenax Therapeutics (TENX) rating to Neutral

    GNG Research Market News

    By GNG Research

    Tenax Therapeutics Inc (TENX) moved from Buy to Neutral at Chardan Capital on August 11, 2026, following a downgrade.

    One of five firms active in the past 90 days rates the stock in the bullish tier. The consensus price targets from 10 analysts as of October 30, 2026, have a mean of $9.82, a median of $5.10 and a range of $4.04 to $36.75.

    Consensus Q4 FY2026 EPS is -$0.36, with revenue at $0. The next earnings report is on March 8, 2027.